Pfizer Corporation

Bend Research, Inc.

Pfizer Products Inc.

Scott Max Herbig

William John Curatolo

James A S Nightingale

Kelly L Smith

Avinash G Thombre

Leah Elizabeth Appel

Dwayne Thomas Friesen

Richard W Korsmeyer

Paul Van Eikeren

James Blair West

Sriram Krishnaswami

Manisha Lamba

Thomas C Stock

Joseph Kushner, Iv

David Keith Lyon

Scott B McCray

Marshall David Crew

Julian B Lo

Jeelin Lo

John R Cardinal

Mary T Am Ende

James William West

Roderick Jack Ray

Edward L Cussler

Daniel J Brose

Hylar Lewis Friedman

Ravi Mysore Shankar

Timothy A Hagen

Avinash Govind Thombre

Timothy Arthur Hagen

Scott Baldwin Mccray

Julian Belknap Lo

Joseph Kushner Iv

James Alan Schriver Nightingale

Joseph Kushner

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

Tofacitinib oral sustained release dosage forms

Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment.

Solid pharmaceutical dispersions with enhanced bioavailability

Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.

Multiparticulate crystalline drug compositions having controlled release profiles

Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of treating a disease or disorder comprising administering such dosage form to a person.

Controlled release by extrusion of solid amorphous dispersions of drugs

The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

Azithromycin dosage forms with reduced side effects

The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation.

Sustained release formulations for growth hormone secretagogues

Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr.

Sertraline salts and sustained-release dosage forms of sertraline

Use of interfacially-polymerized membranes in delivery devices

Growing community of inventors

East Lyme, CT, United States of America

Scott Max Herbig